X4 Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host a Conference Call and Webcast on March 4, 2021
X4 Pharmaceuticals (Nasdaq: XFOR) is set to report its financial results for Q4 and the full year ended December 31, 2020, on March 4, 2021. The announcement includes insights into recent business highlights and will be followed by a conference call at 8:30 a.m. ET. The company specializes in therapies targeting the CXCR4 pathway, with its lead candidate mavorixafor undergoing various clinical trials. X4 aims to address rare diseases and those with limited treatment options, leveraging its expertise at its facilities in Boston and Vienna.
- X4 Pharmaceuticals is progressing its lead candidate mavorixafor in multiple clinical trials, potentially increasing future revenue streams.
- The upcoming financial results announcement may provide clarity on the company's performance and strategic direction.
- None.
BOSTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2020, and provide an update on recent business highlights, on March 4, 2021.
The Company will host a conference call and webcast on the same day at 8:30 a.m. ET to discuss these financial results and business highlights. The conference call can be accessed by dialing (866) 721-7655 from the United States or (409) 216-0009 internationally, followed by the conference ID: 1053189. The live webcast can be accessed on the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com. Following the completion of the call, a webcast replay of the conference call will be available on the website.
About X4 Pharmaceuticals
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. The company’s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials – in combination with ibrutinib in patients with Waldenstrom macroglobulinemia, and as monotherapy in patients with severe congenital neutropenia (SCN). X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at its research facility in Vienna, Austria, and is developing additional product candidates. For more information, please visit www.x4pharma.com.
Investors and Media:
Daniel Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
Mónica Rouco Molina
Senior Account Executive
LifeSci Communications
mroucomolina@lifescicomms.com
FAQ
When will X4 Pharmaceuticals report its Q4 financial results?
What is the focus of X4 Pharmaceuticals?
What is mavorixafor?
What clinical trials is mavorixafor currently undergoing?
What time is the X4 Pharmaceuticals conference call?
